Skip to content

Safety and efficacy of endoscopic retrograde appendicitis therapy versus standard antibiotic treatment for uncomplicated acute appendicitis with appendicolith

Safety and efficacy of endoscopic retrograde appendicitis therapy versus standard antibiotic treatment for uncomplicated acute appendicitis with appendicolith

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126964
Enrollment
Unknown
Registered
2026-06-22
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute appendicitis

Interventions

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older; 2. Uncomplicated acute appendicitis (UAA) suspected based on clinical presentation and definitively diagnosed by radiological imaging (ultrasound (US)/computed tomography (CT)/magnetic resonance imaging (MRI)), with the presence of appendicolith. UAA is defined by the typical symptoms, signs, and imaging findings of acute appendicitis without evidence of perforation, gangrene, abscess/phlegmon, or generalized peritonitis; 3. Written informed consent signed by patients or their family members.

Exclusion criteria

Exclusion criteria: 1. Imaging findings suggestive of appendiceal mucocele or suspected appendiceal neoplasm, or other possible acute abdominal conditions; 2. Immunodeficiency (e.g., absolute neutrophil count < 500/mm³, chronic use of immunosuppressive drugs, active chemotherapy, or AIDS); 3. Women who are pregnant or lactating; 4. Allergy or contraindication to proposed antibiotics or laxatives; 5. Initiation of non-operative management with two or more doses of intravenous antibiotics at an outside institution; 6. Intestinal tuberculosis, or inflammatory bowel disease requiring active medical treatment, or severe intestinal adhesions; 7. Severe organ dysfunction or coagulopathy precludes safe tolerance of colonoscopy or is contraindicated; 8. Malignancy requiring active treatment; 9. Any concurrent illness mandating hospitalization or emergent intervention; 10. Another infection that requires treatment with systemic antibiotics; 11. Patients who are expected to be unable to comply with the study protocol or complete the one-year follow-up; 12. Previous episode of appendicitis; 13. Participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Proportion of patients with treatment success (initial treatment success and the absence of recurrence) at 1 year;

Secondary

MeasureTime frame
Proportion of patients with at least one complication within 1 year;Number and duration of hospital admissions per person within 1 year;Days absent from work or school due to illness per person within 1 year;Number of clinic visits or emergency room visits per person within 1 year;Shift in the distribution of Visual Analogue Scale (VAS) pain score at 48 hours;EQ-5D-5L at 1 year;Decision Regret Scale at 1 year;

Countries

China

Contacts

Public ContactXin Yang

The First Affiliated Hospital of Chongqing Medical University

yxin100@hospital.cqmu.edu.cn+86 138 8377 5022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026